Clinical Trials on Streptococcal Pharyngitis in Finland

Total 43 results

Arto Palmu
GlaxoSmithKline

Completed

Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage

Nasopharyngeal Carriage of Streptococcus Pneumoniae

Finland
GlaxoSmithKline

Completed

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)

Streptococcus Pneumoniae | Infections, Streptococcal

Finland
Finnish Institute for Health and Welfare
Turku University Hospital; GlaxoSmithKline

Completed

Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

Pneumococcal Infections

Finland
GlaxoSmithKline

Completed

Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Streptococcus Pneumoniae | Infections, Streptococcal

Finland
Tampere University Hospital
Turku University Hospital; University of Turku

Active, not recruiting

Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR) (DICAR)

Invasive Group A Beta-Haemolytic Streptococcal Disease

Finland
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

Infections, Streptococcal

Belgium, Sweden, Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Arto Palmu
GlaxoSmithKline

Completed

Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (FinIPcarr)

Pneumococcal Infections

Finland
Oulu University Hospital

Unknown

Tonsillectomy in Recurrent Tonsillitis

Tonsillitis

Finland
Oulu University Hospital

Completed

Recurrent Throat Infections and Tonsillectomy

Tonsillitis | Pharyngitis

Finland
University of Oulu
Tampere University; VTT Technical Research Centre of Finland; Hospital District... and other collaborators

Completed

Intelligent Customer-driven Solution for Children and Their Parents Undergoing Day Surgery

Children | Surgery | Parents | Tonsillitis | Herniorrhaphies

Finland
Helsinki University Central Hospital

Completed

Penicillin and Metronidazole in Treatment of Peritonsillar Abscess

Peritonsillar Abscess

Finland
Turku University Hospital

Recruiting

Intracapsular Tonsillectomy in Adults

Tonsillitis | Tonsillitis Chronic | Tonsil Disease | Tonsillitis Acute

Finland
GlaxoSmithKline

Completed

A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study

Infections, Streptococcal

Finland, France, Poland
Helsinki University Central Hospital

Completed

Targeting of Immune Response After Pneumococcal Vaccination (PncHR)

Pneumococcal Pneumonia

Finland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Infections, Streptococcal

Finland, France, Poland
Finnish Institute for Health and Welfare
Merck Sharp & Dohme LLC; Wyeth-Lederle Vaccines; Pasteur Merieux Connaught

Completed

Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes

Pneumococcal Infections | Otitis Media

Finland
Oulu University Hospital

Completed

Tonsil Surgery in Recurrent or Chronic Tonsillitis

Tonsillitis Chronic | Tonsillitis Recurrent

Finland
Sanofi

Completed

KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges

Pain

France, Russian Federation, Spain, Egypt, Finland, Mexico, Germany
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (PNEU-PLAN)

Pneumococcal Infections

Finland, Malaysia, Poland, Russian Federation, Thailand
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PNEU-PED-EU-2)

Pneumococcal Infections

Denmark, Finland, Italy, Norway, Sweden
Pfizer

Completed

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Pneumococcal Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain
Pfizer

Completed

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

Pneumococcal Infections

United States
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Pneumococcal Disease

Denmark, Belgium, Australia, Poland, Norway, Finland, Netherlands, Italy, Czechia, Estonia, Russian Federation, Slovakia
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Pneumococcal Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Pneumococcal Disease

Spain, United States, Canada, Chile, Greece, Germany, Finland, Argentina, Czechia, Hungary, Puerto Rico
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Pneumococcal Infections

United States, Australia, Canada, Finland, Germany, Israel, Malaysia, Peru, Taiwan, Thailand
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Pneumococcal Infection

United States, Puerto Rico
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Pneumococcal Disease

United States, Sweden
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Pneumococcal Infection

France, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden, Chile, Colombia, Israel, Thailand
Pfizer

Completed

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults

Tonsillitis | Pharyngitis

Belgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Pfizer

Completed

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

United States
Pfizer

Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

United States
Merck Sharp & Dohme LLC

Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (PNEU-TRUE)

Pneumococcal Infections | Pneumonia, Pneumococcal

United States, Australia, Chile, Denmark, Finland, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Pneumonia, Pneumococcal

United States
Pfizer

Completed

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Pneumonia, Pneumococcal | Gram-positive Bacterial Infections | Community Acquired Infections

United States, Slovakia, Spain, Taiwan
BioCryst Pharmaceuticals
Department of Health and Human Services

Completed

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Fatigue | Myalgia | Cough | Headache | Nasal Congestion | Seasonal Influenza | Sore Throat

United States, Mexico, Canada, Australia, New Zealand, Puerto Rico
BioCryst Pharmaceuticals
Department of Health and Human Services

Terminated

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Cough | Fever | Headache | Nasal Congestion | Seasonal Influenza | Sore Throat

United States, Poland, Ukraine, Germany, Belgium, Argentina, Israel, Bulgaria, Serbia, South Africa, Brazil, Canada, Chile, Peru, Russian Federation, Hungary, Czech Republic, India, United Kingdom, Latvia, Bosnia and Herzegovina, ... and more

Clinical Trials on Streptococcal Pharyngitis in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations